9 completed, 4 recruiting, 3 active not recruiting, 2 unknown. 12 Not applicable, 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 12 | Completed 9, Active not recruiting 2, Recruiting 1 |
| Phase 2 | 3 | Active not recruiting 1, Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Other Cancer: new trials by email Literature Review of Other Cancer trials Research Report on Other Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry Proton Transfer Reaction Mass Spectrometry Analysis - Pancreas Cancer, Hepatocellular Carcinoma | Not yet recruiting | University of Oklahoma | 2000 | 2026-10-01 | 2026-07-29 | |
| A Randomised Controlled Trial to Evaluate the Impact of Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application on Cancer Survivors' Quality of Life Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application, Digital application with expert guidelines on lifestyle modification - Breast Cancer, Lung Cancer | Not applicable | Active not recruiting | Complement Theory Inc. | 146 | 2024-05-12 | 2025-12-17 |
| Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS) Ablative local therapy - Breast Cancer, Oligoprogressive | Not applicable | Recruiting | University of California, Davis | 250 | 2023-10-05 | 2026-07-08 |
| Evaluation of Novel Cone-Beam CT for Guidance and Adaptation of Precision Radiotherapy CBCT Imaging - Lung Cancer, Liver Cancer | Not applicable | Completed | Varian, a Siemens Healthineers Company | 31 | 2022-12-20 | 2026-08-26 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) rezatapopt, pembrolizumab - Advanced Solid Tumor, Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | PMV Pharmaceuticals, Inc | 300 | 2020-10-29 | 2026-10-02 |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer | Phase 2 | Unknown | Fondazione per la Medicina Personalizzata | 400 | 2020-10-07 | 2023-10-03 |
| Advance Care Planning: Promoting Effective and Aligned Communication in the Elderly Clinician Communication Skills Training, Advance Care Planning (ACP) Decisions Videos Decisions Aids, Video Declarations (ViDec) - Other Cancer | Not applicable | Completed | Dana-Farber Cancer Institute | 13800 | 2020-04-15 | 2025-10-21 |
| Symptom Management Implementation of Patient Reported Outcomes in Oncology Stakeholder Survey (Control Period), Stakeholder Survey (Intervention Period), Qualitative Interview - Other Cancer, Gastrointestinal Cancer | Not applicable | Completed | Dana-Farber Cancer Institute | 42808 | 2019-07-25 | 2025-08-27 |
| Pilot Feasibility of the Pediatric Cancer Resource Equity (PediCARE) Intervention PediCARE, Usual Care - Other Cancer | Not applicable | Completed | Dana-Farber Cancer Institute | 40 | 2019-05-28 | 2024-09-19 |
| Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) ruxolitinib - Other Cancer | Phase 2 | Active not recruiting | Massachusetts General Hospital | 50 | 2019-04-19 | 2025-11-10 |
| A Geriatric Oncology Collaborative Care Intervention for Older Adults With Advanced Cancer Usual Care, Geriatric Oncology Collaborative Care - Other Cancer | Not applicable | Completed | Massachusetts General Hospital | 91 | 2019-02-14 | 2022-04-07 |
| Multimodal Mobile Intervention Application (App) to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant Survivors Mobile App + enhanced standard care, Enhanced Standard Care - Other Cancer | Not applicable | Completed | Massachusetts General Hospital | 60 | 2019-02-01 | 2026-09-24 |
| Testing Feasibility of Motivational Interviewing for Patient-Reported Cancer Pain Goals Motivational Interviewing - Other Cancer | Not applicable | Completed | Dana-Farber Cancer Institute | 54 | 2018-11-16 | 2022-04-25 |
| SHARE (Sharing Goals and Preferences) Study More Good Days video&brief questionnaire - Other Cancer | Not applicable | Completed | Dana-Farber Cancer Institute | 53 | 2018-07-23 | 2022-03-17 |
| Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation Shared Care, Standard Care - Other Cancer | Not applicable | Completed | Dana-Farber Cancer Institute | 404 | 2018-01-01 | 2024-08-16 |
| Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients Nasopharyngeal Cancer, Prostate Cancer | Recruiting | National Cancer Centre, Singapore | 5000 | 2015-09-30 | 2025-06-11 | |
| Circulating Tumor DNA Exposure in Peripheral Blood Colorectal Cancer, Pancreatic Adenocarcinoma | Unknown | Quantgene Inc. | 10000 | 2015-01-01 | 2018-11-20 | |
| Development of an Intervention to Enhance Cancer Pain Management Enhancing Cancer Pain Management - Other Cancer | Not applicable | Active not recruiting | Massachusetts General Hospital | 150 | 2014-04-15 | 2026-03-27 |
| Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions Genetic screening - Pheochromocytoma, Paraganglioma | Recruiting | The University of Texas Health Science Center at San Antonio | 2000 | 2005-10-19 | 2025-10-15 |
Breast Neoplasms (7) · Lung Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (3) · Head and Neck Neoplasms (3) · Ovarian Neoplasms (3) · Prostatic Neoplasms (3) · Carcinoma, Hepatocellular (2) · Gastrointestinal Neoplasms (2) · Neoplasms (2) · Urinary Bladder Neoplasms (2) · Adrenal Cortex Neoplasms (1) · Bone Neoplasms (1) · Colonic Neoplasms (1) · Endometrial Neoplasms (1)
Neoplasms (10) · Neoplasms by Site (10) · Breast Diseases (7) · Digestive System Diseases (7) · Digestive System Neoplasms (7) · Skin Diseases (7) · Skin and Connective Tissue Diseases (7) · Gastrointestinal Diseases (6) · Lung Diseases (6) · Male Urogenital Diseases (6) · Respiratory Tract Diseases (6) · Respiratory Tract Neoplasms (6) · Thoracic Neoplasms (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6)
Ado-Trastuzumab Emtansine (1) · Advance Care Planning (1) · Alpelisib (1) · Erlotinib Hydrochloride (1) · Everolimus (1) · Genetic Testing (1) · Ipilimumab (1) · Lapatinib (1) · Motivational Interviewing (1) · Nivolumab (1) · Standard of Care (1) · Trastuzumab (1) · Vemurafenib (1) · alectinib (1) · atezolizumab (1)
Dana-Farber Cancer Institute (6) · Massachusetts General Hospital (4) · Complement Theory Inc. (1) · Fondazione per la Medicina Personalizzata (1) · National Cancer Centre, Singapore (1) · PMV Pharmaceuticals, Inc (1) · Quantgene Inc. (1) · The University of Texas Health Science Center at San Antonio (1) · University of California, Davis (1) · University of Oklahoma (1) · Varian, a Siemens Healthineers Company (1)
United States (16) · Italy (2) · Singapore (2) · Australia (1) · Canada (1) · France (1) · Germany (1) · South Korea (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Andrea Botticelli (1) · Areej El-Jawahri, MD (1) · Claudio L. Battaglini, PhD (1) · Erik Hanson, PhD (1) · Gregory A. Abel, MD MPH (1) · James A. Tulsky, MD (1) · Kira Bona, MD (1) · Lara Traeger, MD (1) · Marc Fellous, MD (1) · Melvin Chua, MD (1) · Michael Hassett, MD (1) · Nancy L Keating, MD (1) · Nirmal Choradia, MD (1) · Olga Ehrlich, PhD (1) · Paolo Marchetti (1)
PMID 31452053, PMID 31463699, PMID 32665394, PMID 33826860, PMID 34985914, PMID 35736783, PMID 38011613, PMID 38445744, PMID 38485149, PMID 38819828, PMID 39365992, PMID 39486014, PMID 39533260, PMID 39786764, PMID 40257368, PMID 40343696, PMID 40490014, PMID 40524282, PMID 40543428, PMID 40631021, PMID 40932470, PMID 41023484, PMID 41740031, PMID 41941188, PMID 41963505
1UM1CA233080-01 (1), 2018 (1), K07CA211847 (1), K12CA087723 (1), P30CA093373 (1), R01CA264248 (1), R01GM114102 (1), UG3AG060626 (1)